Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

23.10 -0.30 (-1.28%)
Streaming Delayed Price Updated: 2:29 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 686,555
Open 23.56
Bid (Size) 23.10 (1)
Ask (Size) 23.11 (3)
Prev. Close 23.40
Today's Range 23.08 - 23.74
52wk Range 13.73 - 33.99
Shares Outstanding 162,625,379
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire

Performance

YTD
+41.54%
+41.54%
1 Month
-20.59%
-20.59%
3 Month
-3.91%
-3.91%
6 Month
+26.09%
+26.09%
1 Year
+35.33%
+35.33%

More News

Read More
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
Via The Motley Fool
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?
Via The Motley Fool
Analyst Expectations for ACADIA Pharmaceuticals's Future
Via Benzinga
ACADIA Pharmaceuticals's Earnings: A Preview
Via Benzinga
Why Acadia Pharmaceuticals Stock Is Soaring Today
Via The Motley Fool
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
Via The Motley Fool
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
JP Morgan Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves
Via MarketBeat
Nasdaq Drops 50 Points; Wells Fargo Earnings Beat Views
Via Benzinga
Reassuring Market Adoption of Daybue Fuels Acadia's Strategic Advancements, Analysts Boost Price Targets
Via Benzinga
Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Crude Oil Down 2%; Citigroup Profit Tops Estimates
Via Benzinga
Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High
Via Investor's Business Daily
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Are Acadia Pharmaceuticals Shares Trading Higher Today?
Via Benzinga
Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Microsoft To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.